At any one time the University of Oxford sponsors around 1,000 academic designed and led clinical research studies within the EU of which about 150 are interventional trials ranging from phase I to phase IV. The University sponsors approximately 350 further studies outside the EU, largely through its Centre for Tropical Medicine and Global Health.
Often in partnership with Oxford University Hospitals Foundation NHS Trust or Oxford Health Foundation NHS Trust most of the EU-based studies are run by one of the University’s six UKCRC fully registered specialist clinical trials units:
- Clinical Trial Service Unit and Epidemiological Studies Unit specializing in major large scale studies and trials of chronic disease;
- Diabetes Trials Unit national and multinational trials of the management and treatment of diabetes;
- Oxford Clinical Trials Research Unit which integrates the following trials groups:
- Oxford Trauma and Emergency Care
- Oncology Clinical Trials Office
- Surgical Intervention Trials Unit
- Experimental Medicine and Rheumatology
- Centre for Rehabilitation Research in Oxford
- NPEU Clinical Trials Unit conducts multicentre trials of a broad range of interventions for women and their families during pregnancy, childbirth, the newborn period and early childhood;
- Primary Care and Vaccines Collaborative Clinical Trials Unit which integrates the Primary Care Trials Unit and the Oxford Vaccine Centre.
c. 1,000 academic designed and led clinical research studies within the EU
Approximately 350 further studies outside the EU
Clinical Trials News
Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination
29 June 2022
The Oxford Clinical Trials Research Unit at Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) played a key role in the Vaccine Response On Off Methotrexate (VROOM) study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.
29 April 2022
Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.
25 April 2022
Patient recruitment is on-track in the Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa.